Business Trends– category –
-
Capricor Therapeutics Establishes Commercial Manufacturing for Deramiocel Cell Therapy for DMD, Reports Q2 2026 Financials
Capricor Therapeutics USA Overview Capricor Therapeutics reported its Q2 2026 financial results, highlighting commercial and manufacturing readiness for its lead product candidate, Deramiocel. This allogeneic cardiac-derived cell therapy... -
Porton Advanced Secures China NMPA Drug License to Expand CDMO Services to Commercial CGT Manufacturing
Porton Advanced China Overview Porton Advanced has been granted a Class C Drug Manufacturing License by China's NMPA, enabling it to undertake commercial contract manufacturing for Cell and Gene Therapy (CGT) products. This expands their... -
NueCell Bio Launches 26,300-Square-Foot Cell Therapy Development Facility to Scale CDMO Services in San Diego
PharmaSource USA Overview NueCell Bio has launched as a dedicated cell therapy science and development services company, opening a 26,300-square-foot facility in San Diego to support translational development, process development, analyt... -
Xilio Therapeutics Reports Q2 2026 Financial Results, Advances Tumor Microenvironment-Activated Immunotherapy Pipeline with Promising Early Clinical Data
GlobeNewswire USA Overview Xilio Therapeutics released its Q2 2026 financial results, reporting significant pipeline progress for its tumor microenvironment (TME)-activated immunotherapy candidates. Lead programs XTX101, XTX202, and XTX3... -
Voyager Therapeutics Advances Two Tau-Targeted Alzheimer’s Therapies Towards Key Clinical Milestones
NeurologyLive USA Overview Voyager Therapeutics announced its progression of two innovative therapeutic candidates targeting tau protein, a key pathological hallmark of Alzheimer's disease, toward significant clinical milestones. These c... -
RegMedNet Highlights Specialized Partnerships to Overcome Cell Therapy Challenges: New Strategies for Accelerated Commercialization
RegMedNet Unknown Overview RegMedNet's latest 'Cell Therapy Weekly' edition spotlights emerging specialized partnerships aimed at resolving critical challenges in the cell therapy sector. These collaborations focus on streamlining comple... -
Children’s Hospital Los Angeles Joins Multi-Center Trial for In Vivo CRISPR Gene Editing Therapy for Sickle Cell Disease
Children's Hospital Los Angeles (CHLA) Facebook USA Overview Children's Hospital Los Angeles (CHLA) has announced its participation in a multi-center clinical trial evaluating a novel CRISPR-based, direct gene editing therapy for sickle ... -
CRISPR Gene Editing Achieves Clinical Breakthroughs in Sickle Cell Disease Treatment
Liv Hospital Turkey Overview Clinical trials employing CRISPR gene-editing technology for sickle cell disease are reporting highly promising results, significantly reducing severe vaso-occlusive crises and transfusion dependency. Utilizi... -
CRISPR Cancer Therapy 2026: 32 Clinical Trials Underway, Gene-Edited T-Cells Face Efficacy and Off-Target Challenges
Hirschfeld Oncology USA Overview As of 2026, 32 clinical trials are investigating CRISPR-edited immunotherapies for cancer, predominantly focusing on ex vivo gene-edited immune cells. While these therapies generally demonstrate favorable... -
FDA Approves Orca-T Precision Treg Cell Therapy, Reducing Chronic GVHD Risk and Boosting Survival in Blood Cancer Patients Undergoing Matched Donor Transplants
AJMC (American Journal of Managed Care) USA Overview The U.S. FDA has approved Orca-T precision Treg cell therapy, designed to reduce the risk of chronic graft-versus-host disease (GVHD) and improve survival rates in blood cancer patient...
